Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Asset disposition
Inv. presentation
Acq. announced
|
|
OPKO HEALTH, INC. (OPK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/06/2018 |
8-K
| Quarterly results |
| 09/07/2017 |
8-K
| Quarterly results |
| 01/10/2017 |
8-K
| Form 8-K - Current report |
| 09/24/2015 |
8-K
| Investor presentation |
| 06/10/2015 |
8-K
| Investor presentation |
| 01/14/2015 |
8-K
| Investor presentation |
| 06/03/2014 |
8-K
| Investor presentation |
| 09/11/2013 |
8-K
| Form 8-K - Current report |
| 06/04/2013 |
8-K
| Investor presentation |
| 01/09/2013 |
8-K
| Investor presentation|
Docs:
|
"OPKO HEALTH TO ACQUIRE TWO PHASE 3 PRODUCTS New Vitamin D Prohormone and Phosphate Binder for Kidney Disease Patients MIAMI—January 8, 2013 — OPKO Health, Inc. has entered into a definitive agreement to acquire Cytochroma Inc. whose lead products, both in phase 3 clinical trials, are Replidea™ , a vitamin D prohormone to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency, and Alpharen™, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. Replidea™ has been shown in a phase 2b clinical trial to effectively and safely treat SHPT and the underlying vitamin D insufficiency in pre-dialysis patients. Vitamin D insufficiency arises in CKD due to the abnormal upregulation of CYP24, an enzyme which destro...",
"Seller Corporate Presentation January, 2013" |
|
| 06/07/2012 |
8-K
| Form 8-K - Current report |
| 11/17/2009 |
8-K
| Form 8-K - Current report |
| 09/24/2009 |
8-K
| Form 8-K - Current report |
|
|